HER2 drives breast cancer cell stemness in both luminal and HER2-positive breast cancer [193,194,195,196], raising the potential to use anti-HER2 therapy in all breast cancers where BCSCs express HER2. This evidence concerns the gene ERBB2 and breast cancer.